Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jun 14:11:2050313X231180775.
doi: 10.1177/2050313X231180775. eCollection 2023.

Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report

Alex Nguyen  1 , Kathleen D'Aguanno  1 , Zainab Ridha  2 , Alexander Tsoukas  3 , Elena Netchiporouk  2
Affiliations
Case Reports

Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report

Alex Nguyen et al. SAGE Open Med Case Rep. .

Abstract

Acrodermatitis continua of Hallopeau is a rare, localized variant of pustular psoriasis commonly associated with join disease and severe quality of life impairment. While there are no standard treatment guidelines, therapies used for psoriasis vulgaris are commonly tried. We report a case of severe acrodermatitis continua of Hallopeau in a patient with multiple comorbidities (advanced malignancy, recurrent empyema, psoriatic arthritis) where tildrakizumab lead to a rapid resolution of skin and joint disease which was maintained 1 year later. To date, there are only four cases reporting the use of IL-23 inhibitors class in acrodermatitis continua of Hallopeau and none for tildrakizumab. However, IL-23 inhibitors should be strongly considered among the treatment of choice for acrodermatitis continua of Hallopeau, especially in patients with ongoing malignancy and/or high risk of infections.

Keywords: Psoriasis; acrodermatitis continua of Hallopeau; tildrakizumab.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: E.N. has received investigator-initiated research support and/or acted as a consultant and/or speaker for Sun Pharma, Novartis, AbbVie, Beiersdorf, Leo Pharma, Eli Lilly, Sanofi, Bausch Health, BMS, Janssen, Mallinckrodt, UCB, Medexus, Boehringer Ingelheim, Eli Lilly, Galderma, Sandoz.

Figures

Figure 1.
Figure 1.
Clinical findings on initial presentation. (a) and (b) illustrate erythema and swelling of the distal digits, pustules, nail hyperkeratosis, and detachment. Of note, these pictures were taken following intralesional corticosteroids injection and ultrapotent topical corticosteroid use.
Figure 2.
Figure 2.
Clinical finding after > 1 year of treatment. (a) and (b) show complete remission of skin and nail disease.
See this image and copyright information in PMC

References

    1. Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol 2018; 178(3): 614–618. - PubMed
    1. Bhate C, Schwartz RA. Acrodermatitis continua of Hallopeau: historical perspectives and modern management. Ital J Dermatol Venerol 2022; 157(2): 132–136. - PubMed
    1. Smith MP, Ly K, Thibodeaux Q, et al.. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl) 2019; 9: 65–72. - PMC - PubMed
    1. Maliyar K, Crowley EL, Rodriguez-Bolanos F, et al.. The use of biologic therapy in the treatment of acrodermatitis continua of Hallopeau: a review. J Cutan Med Surg 2019; 23(4): 428–435. doi: 10.1177/1203475419836435 - DOI - PubMed
    1. Langer N, Wilsmann-Theis D, Kromer C, et al.. Successful therapy of acrodermatitis continua of Hallopeau with IL-23 blockers—two new cases. J Dtsch Dermatol Ges 2021; 19(10): 1504–1507. - PubMed

Publication types

LinkOut - more resources